ArticlePloS one2013
Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04765033 (Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease), which is not on this map. Cited by 102 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Nebulised 5% Hypertonic Saline in Children With Chronic Suppurative Lung Disease
Who cites it
102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Bacteria of the lung microbiome and health biomarkers in chronic airway disease: a systematic review and meta-analysis.NPJ biofilms and microbiomes · 2026Pooled it
- Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis.Redox biology · 2020Pooled it
- Bolus Weekly Vitamin D3 Supplementation Impacts Gut and Airway Microbiota in Adults With Cystic Fibrosis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.The Journal of clinical endocrinology and metabolism · 2018Trial
- Esophageal microbiome in eosinophilic esophagitis.PloS one · 2015Trial
- Review
- Article
- Genomic diversity inMicrobial genomics · 2025Article
- Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development.mSystems · 2023Article
- Infection, Allergy, and Inflammation: The Role ofMicroorganisms · 2023Review
- Oral bacterial composition associated with lung function and lung inflammation in a community-based Norwegian population.Respiratory research · 2023Article
- Upper airway microbiota development in infants with cystic fibrosis diagnosed by newborn screen.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis.Scientific reports · 2023Observational
- Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system.eLife · 2023Article
- Commensal bacteria of the lung microbiota synergistically inhibit inflammation in a three-dimensional epithelial cell model.Frontiers in immunology · 2023Article
- Antibiotics Drive Expansion of Rare Pathogens in a Chronic Infection Microbiome Model.mSphere · 2022Article
- Impact of Antibiotics on the Lung Microbiome and Lung Function in Children With Cystic Fibrosis 1 Year After Hospitalization for an Initial Pulmonary Exacerbation.Open forum infectious diseases · 2022Article
- Article
- Nontypeable Haemophilus influenzae Infection Impedes Pseudomonas aeruginosa Colonization and Persistence in Mouse Respiratory Tract.Infection and immunity · 2022Article
- Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPulmonary exacerbations (PEx), frequently associated with airway infection and inflammation, are the leading cause of morbidity in cystic fibrosis (CF). Molecular microbiologic approaches detect complex microbiota from CF airway samples taken during PEx. The relationship between airway microbiota, inflammation, and lung function during CF PEx is not well understood.
objectiveTo determine the relationships between airway microbiota, inflammation, and lung function in CF subjects treated for PEx.
methodsExpectorated sputum and blood were collected and lung function testing performed in CF subjects during early (0-3d.) and late treatment (>7d.) for PEx. Sputum was analyzed by culture, pyrosequencing of 16S rRNA amplicons, and quantitative PCR for total and specific bacteria. Sputum IL-8 and neutrophil elastase (NE); and circulating C-reactive protein (CRP) were measured.
resultsThirty-seven sputum samples were collected from 21 CF subjects. At early treatment, lower diversity was associated with high relative abundance (RA) of Pseudomonas (r = -0.67, p<0.001), decreased FEV(1%) predicted (r = 0.49, p = 0.03) and increased CRP (r = -0.58, p = 0.01). In contrast to Pseudomonas, obligate and facultative anaerobic genera were associated with less inflammation and higher FEV₁. With treatment, Pseudomonas RA and P. aeruginosa by qPCR decreased while anaerobic genera showed marked variability in response. Change in RA of Prevotella was associated with more variability in FEV₁ response to treatment than Pseudomonas or Staphylococcus.
conclusionsAnaerobes identified from sputum by sequencing are associated with less inflammation and higher lung function compared to Pseudomonas at early exacerbation. CF PEx treatment results in variable changes of anaerobic genera suggesting the need for larger studies particularly of patients without traditional CF pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.